Patents by Inventor Kasper Lamberth

Kasper Lamberth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII variants having a decreased cellular uptake
    Patent number: 10906960
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: February 2, 2021
    Assignee: SANQUIN BLOOD SUPPLY FOUNDATION
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII Variants Having A Decreased Cellular Uptake
    Publication number: 20180327479
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: July 6, 2018
    Publication date: November 15, 2018
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 10047142
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 14, 2018
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20170066813
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: November 18, 2016
    Publication date: March 9, 2017
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnes Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • Factor VIII variants having a decreased cellular uptake
    Patent number: 9321827
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 26, 2016
    Assignees: Novo Nordisk A/S, Sanquin Blood Supply Foundation
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20160002314
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 23, 2015
    Publication date: January 7, 2016
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Kjalke, Henning Ralf Stennicke, Johannes Jacobus Voorberg, Maartje Van Den Biggelaar
  • THERAPEUTIC FACTOR VIII ANTIBODIES
    Publication number: 20150239984
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Application
    Filed: May 12, 2015
    Publication date: August 27, 2015
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi L. Holmberg, Kasper Lamberth, Jes T. Clausen
  • Therapeutic factor VIII antibodies
    Patent number: 9062115
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: June 23, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi Lindgreen Holmberg, Kasper Lamberth, Jes Thorn Clausen
  • FACTOR VIII VARIANTS HAVING A DECREASED CELLULAR UPTAKE
    Publication number: 20140057848
    Abstract: The present invention relates to modified coagulation factors. In particular, the present invention relates to modified Factor VIII molecules having decreased cellular uptake.
    Type: Application
    Filed: September 14, 2011
    Publication date: February 27, 2014
    Applicant: NOVO NORDISK A/S
    Inventors: Henriet Meems, Alexander Benjamin Meijer, Koenraad Mertens, Ole Hvilsted Olsen, Kasper Lamberth, Peder Lisby Noerby, Laust Bruun Johnsen, Marianne Hjortnæs Kjalke, Henning Ralf Stennicke, Johannes Voorberg, Maartje Van Den Biggelaar
  • THERAPEUTIC FACTOR VIII ANTIBODIES
    Publication number: 20130266576
    Abstract: The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.
    Type: Application
    Filed: September 15, 2011
    Publication date: October 10, 2013
    Applicant: NOVO NORDISK A/S
    Inventors: Henrik Oestergaard, Ida Hilden, Heidi Lindgreen Holmberg, Kasper Lamberth, Jes Thorn Clausen